Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Nanosilver
... 14.5% over the analysis period 2024-2030. Healthcare & Life Sciences End-Use, one of the segments analyzed in the report, is expected to record a 15.8% CAGR and reach US$3.5 Billion by the end of the ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Gastrointestinal Therapeutics
... CAGR of 5.1% over the analysis period 2024-2030. Crohn`s Disease End-Use, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$19.0 Billion by the end of the ... Read More
-
Gynecological Cancer Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$12.1 Billion by the end of ... Read More
-
Critical Care Therapeutics
... at a CAGR of 5.7% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$3.7 Billion by the end of the ... Read More
-
Gastroparesis Drugs
... CAGR of 4.8% over the analysis period 2024-2030. Idiopathic Gastroparesis Drugs, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$4.3 Billion by the end of the ... Read More
-
Leukemia Therapeutics
... CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia Therapeutics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of ... Read More
-
Myasthenia Gravis Drugs
... at a CAGR of 6.6% over the analysis period 2024-2030. Drug Treatment, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Schizophrenia Therapeutics
... CAGR of 4.2% over the analysis period 2024-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$7.7 Billion by the end of ... Read More
-
Glioblastoma Multiforme Treatment (GBM)
... 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Radiation Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the ... Read More
-
Periodontal Therapeutics
... CAGR of 8.6% over the analysis period 2024-2030. Systemic Antibiotics, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$623.3 Million by the end of the analysis ... Read More
-
Plasma Protein Therapeutics
... at a CAGR of 4.8% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$9.3 Billion by the end of the ... Read More
-
Respiratory Syncytial Virus (RSV) Therapeutics
... Billion by 2030, growing at a CAGR of 29.2% over the analysis period 2024-2030. Prophylaxis Drugs, one of the segments analyzed in the report, is expected to record a 28.4% CAGR and reach US$7.6 Billion ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Hypercalcemia Treatment
... CAGR of 9.3% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$28.0 Billion by the end of the analysis period. ... Read More
-
Krabbe Disease Treatment
... at a CAGR of 6.2% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$823.5 Million by the end of the ... Read More
-
Diabetic Macular Edema Treatment
... 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Anti-VEGF, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$2.7 Billion by the end ... Read More
-
Male Hypogonadism
... CAGR of 5.1% over the analysis period 2024-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.5 Billion by the end of the ... Read More
-
Microbiome Therapeutics
... CAGR of 56.8% over the analysis period 2024-2030. C. Difficile Infection Indication, one of the segments analyzed in the report, is expected to record a 53.0% CAGR and reach US$7.3 Billion by the end of ... Read More
-
MRSA Drugs
... CAGR of 4.5% over the analysis period 2024-2030. Glycopeptides & Lipoglycopeptides, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$726.5 Million by the end of the ... Read More
-
Organs-on-Chips
... 35.3% over the analysis period 2024-2030. Liver-on-a- Chip, one of the segments analyzed in the report, is expected to record a 36.6% CAGR and reach US$206.0 Billion by the end of the analysis period. Growth ... Read More
-
Post-Traumatic Stress Disorder (PTSD) Therapeutics
... Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.1 Billion by ... Read More
-
Pruritus Therapeutics
... CAGR of 4.6% over the analysis period 2024-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.7 Billion by the end of the analysis period. ... Read More
-
Single-Use Bioprocessing
... CAGR of 20.8% over the analysis period 2024-2030. Single-Use Media Bags & Containers, one of the segments analyzed in the report, is expected to record a 22.6% CAGR and reach US$29.9 Billion by the end ... Read More
-
Non-Small Cell Lung Cancer (NSCLC) Therapeutics
... reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach ... Read More
Research Assistance
